Edition:
United States

People: Inovio Pharmaceuticals Inc (INO.O)

INO.O on Nasdaq

6.86USD
2 Dec 2016
Change (% chg)

$0.04 (+0.59%)
Prev Close
$6.82
Open
$6.82
Day's High
$7.09
Day's Low
$6.78
Volume
918,054
Avg. Vol
1,197,868
52-wk High
$11.69
52-wk Low
$4.50

Kim, J. Joseph 

Dr. J. Joseph Kim is President, Chief Executive Officer, Director of Inovio Pharmaceuticals Inc. He joined the Company as Chief Executive Officer and a director on June 1, 2009 and also became President on October 6, 2009. He was co-founder of VGX Pharmaceuticals, Inc., or VGX, and its former President, Chief Executive Officer and a director from 2000 to June 2009. Prior to joining VGX, Dr. Kim led efforts in manufacturing and process development of several FDA-approved products and developmental therapeutics at Merck. These products include FDA-approved vaccines for Hepatitis as well as developmental vaccines and therapeutics for HIV/AIDS. Dr. Kim has published over 100 peer-reviewed scientific papers and book chapters, holds numerous patents and sits on several editorial boards and review panels. In 2002, Dr. Kim was named as one of the world’s top 100 young innovators by Technology Review magazine and as one of the “40 under 40” by the Philadelphia Business Journal, which highlights the most dynamic professionals who are under 40 years of age in the region. Dr. Kim was also selected on the list of the “50 Most Influential Men” in the October 2003 and in the October 2006 Power Issue” of Details Magazine. In 2004, Dr. Kim and VGX were selected as one of 30 Technology Pioneers by the World Economic Forum. Furthermore, Dr. Kim was featured in the “Who’s Next 2005” issue of Newsweek International, which included a group of 10 leaders, scientists, and executives at the forefront of change and impact in the world. He holds a Ph.D. in Biochemical Engineering from the University of Pennsylvania and an MBA in Finance from the Wharton School.

Basic Compensation

Total Annual Compensation, USD 964,664
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 1,139,730
Fiscal Year Total, USD 2,104,390

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Avtar Dhillon

657,202

J. Joseph Kim

2,104,390

Peter Kies

1,141,710

Niranjan Sardesai

1,158,040

Mark Bagarazzi

1,161,760

David Weiner

--
As Of  30 Dec 2014